Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

In the Spotlight

Tales of Antigen Evasion from CAR Therapy

Michel Sadelain
Michel Sadelain
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m-sadelain@ski.mskcc.org
DOI: 10.1158/2326-6066.CIR-16-0089 Published June 2016
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Both T cells bearing chimeric antigen receptors and tumor-specific antibodies can successfully target some malignancies, but antigen escape can lead to relapse. Two articles in this issue of Cancer Immunology Research explore what effective countermeasures may prevent it. Cancer Immunol Res; 4(6); 473–473. ©2016 AACR.

See articles by Zah et al., p. 498, and Rufener et al., p. 509.

The use of chimeric antigen receptors (CAR) for cancer immunotherapy is gaining momentum, propelled by the CD19 paradigm (1). CARs are synthetic receptors that retarget T cells to selected antigens and, depending on their design, reprogram T-cell functionality, metabolism, and persistence. The pursuit of CD19 as the target antigen has resulted in remarkable clinical results in patients with B-cell malignancies, especially acute lymphoblastic leukemia (1), and has rapidly generated substantial knowledge on the therapeutic potential and limitations of second-generation CARs. Thus, CARs effectively target both CD4+ and CD8+ T cells against tumors; CD19 CARs can induce complete responses in patients with chemorefractory disease and patients for whom an allogeneic bone marrow transplant would have very little chance of success, and CAR T cells can be manufactured for the vast majority of patients. Based on these exciting outcomes, research on CAR therapy is rapidly expanding in both academia and industry.

Trials of CD19 CAR therapy have also yielded valuable insights into the complications and limitations of this approach. Current CD19 CAR therapy is more effective in acute lymphoblastic leukemia (ALL) than in chronic lymphocytic leukemia or non-Hodgkin lymphoma, for unknown reasons. CD19 CAR T cells occasionally induce strong cytokine responses that require a medical intervention, as well as transient neurotoxicity, which also awaits a mechanistic explanation. Finally, some tumors may resist CD19 CAR therapy or relapse, most often within the first year after CAR T-cell infusion. The relapsed tumors may still express CD19, or read out as CD19-negative, a relatively common occurrence in post-CAR therapy relapse of pediatric ALL (2). Antigen escape is a classic mechanism of tumor immune evasion.

Two research articles in this issue of Cancer Immunology Research shed new light on antigen escape in the context of CAR therapy (3, 4). In the first study, researchers from Yvonne Chen's group (Zah et al.; ref. 2) explore a novel dual targeting CAR design, which they term OR-gate, as a means to minimize the escape of an antigen-negative variant. Dual targeting strategies have been previously reported, either admixing two CAR T-cell populations, coexpressing two CARs in the same T cells, or generating a bispecific CAR. The OR-gate approach differs in that a single CAR is used to target both antigens, CD19 and CD20. The authors demonstrate that their bispecific CAR effectively kills targets expressing either antigen, similarly to a monospecific CAR. This CAR design is simple in concept but challenging to implement. One of the peculiarities of CARs is that they do not engage epitopes at a constant distance from the cell surface, in contrast to the physiologic T-cell receptor (TCR), which binds to a myriad of peptides and HLA molecules under constant spatial constraints. This topology is critical to the productive formation of a T-cell synapse with the antigen-presenting cell. This constraint needs to be adjusted for each CAR and further reconciled for each epitope within the structure of a dual-specific CAR. These authors resolved this issue by selecting epitopes, one on CD19 and the other on CD20, such that each one was positioned within its optimal spatial range. This elegant resolution places a significant restriction on the ability to pair epitopes. Most gratifyingly, however, this approach prevented the emergence of CD19- or CD20-negative escape variants in the context of mixed tumor populations.

Researchers from Brian Till's group (Rufener et al.; ref. 4) explore another circumstance that could precipitate antigen escape, in the scenario where an antibody could mask the CAR target. This may plausibly occur in subjects infused with CD20 CARs after being treated with the CD20-specific monoclonal antibody rituximab. This concern was previously explored when targeting antigens known to be cell bound as well as secreted, such as carcino-embryonic antigen (CEA) or Lewis-Y antigen, in which moderate concentrations of soluble antigen did not preclude CAR target recognition. Rufener and colleagues looked at a broad range of antibody concentrations and their effect on CD20 recognition. Antibody levels as high as 100 μg/mL did not impede CAR T-cell function against high-expressing CD20 lymphoma cell lines—a concentration exceeding the median residual serum rituximab measured in 103 patients with lymphoma. In vivo, rituximab administration did not inhibit CAR T-cell–mediated rejection of rituximab-refractory cell lines. Recipients of rituximab are thus unlikely to resist CD20 CAR T cells and should not be excluded from CAR therapy protocols.

These studies not only bring more good news for the prospects of CAR therapy—they also illustrate the rapid pace of progress in the CAR field.

Disclosure of Potential Conflicts of Interest

The author reports having an ownership interest and serving as a consultant for Juno Therapeutics.

  • ©2016 American Association for Cancer Research.

References

  1. 1.↵
    1. Sadelain M
    . CAR therapy: the CD19 paradigm. J Clin Invest 2015;125:3392–400.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Sotillo E,
    2. Barrett DM,
    3. Black KL,
    4. Bagashev A,
    5. Oldridge D,
    6. Wu G,
    7. et al.
    Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 2015;5:1282–95.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Zah E,
    2. Lin MY,
    3. Silva-Benedict A,
    4. Jensen MC,
    5. Chen YY
    . T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res 2016;4:498–508.
    OpenUrl
  4. 4.↵
    1. Rufener G,
    2. Press OW,
    3. Olsen P,
    4. Lee SY,
    5. Jensen M,
    6. Gopal AK,
    7. et al.
    Preserved activity of CD20-specific chimeric antigen receptor-expressing T cells in the presence of rituximab. Cancer Immunol Res 2016;4:509–19.
    OpenUrl
PreviousNext
Back to top
Cancer Immunology Research: 4 (6)
June 2016
Volume 4, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tales of Antigen Evasion from CAR Therapy
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tales of Antigen Evasion from CAR Therapy
Michel Sadelain
Cancer Immunol Res June 1 2016 (4) (6) 473; DOI: 10.1158/2326-6066.CIR-16-0089

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tales of Antigen Evasion from CAR Therapy
Michel Sadelain
Cancer Immunol Res June 1 2016 (4) (6) 473; DOI: 10.1158/2326-6066.CIR-16-0089
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • How to Reprogram Myeloma-Associated Macrophages: Target IKZF1
  • Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2
  • TGFβ: Protecting PD-1 from mRNA Decay
Show more In the Spotlight
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement